Kenneth F. Bartizal
Plus aucun poste en cours
Profil
Kenneth F.
Bartizal worked as a Research Scientist at Pfizer Inc. from 1986 to 1988.
He was a Faculty Member at Truman State University from 1983 to 1986 and at Kirksville College of Osteopathic Medicine, Inc. from 1983 to 1986.
He served as Executive Director & Head-Infectious Diseases at Merck & Co., Inc. from 2007 to 2007 and as Chief Development Officer at Trius Therapeutics, Inc. from 2007 to 2014.
He also worked as Principal at Pfizer Central Research and as Chief Development Officer at Cidara Therapeutics, Inc. Dr. Bartizal received his undergraduate, graduate, and doctorate degrees from the University of Notre Dame.
Anciens postes connus de Kenneth F. Bartizal
| Sociétés | Poste | Fin |
|---|---|---|
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Director/Board Member | 01/04/2007 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/1988 |
| Kirksville College of Osteopathic Medicine, Inc. | Corporate Officer/Principal | - |
| Truman State University | Corporate Officer/Principal | - |
Formation de Kenneth F. Bartizal
| University of Notre Dame | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
| Pfizer Central Research |
